The Post Traumatic Stress Disorder (PTSD) Checklist for DSM-5 (PCL-5) is a 20-item self-report measure of the twenty DSM-5 symptoms of PTSD in adult populations (ages 18+). It is designed for use with people who have experienced traumatic events.
The PCL-5 is widely used in clinical and research settings to screen for PTSD, assess symptom severity, and monitor treatment progress over time (Forkus et al., 2023).Total scores can range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Percentiles are also presented for the total score in comparison to both a normative and clinical (PTSD) sample. A normative percentile of 50 is indicative of an average score for someone who does not have PTSD, whereas a PTSD percentile of 50 is indicative of an average score for someone who is currently in care for PTSD.
There are four subscales which match the four symptom clusters for PTSD within DSM-5:
In addition to a raw score being presented, a mean score is also computed, which is the subscale score divided by the number of items within that subscale. The average score can help determine elevated symptom clusters when comparing each of the four subscales. These scores range between 0 to 4, where higher scores represent higher severity. Consistent with the likert scale:
Symptom descriptors are also presented for the total score and each of the subscale scores. These descriptors are determined by the distance from the normative mean:
Given the PCL-5 questions closely reassembled the diagnostic criteria in the DSM-5-TR, a provisional PTSD diagnosis can be made based on the following rule. The DSM-5 diagnostic criteria requires at least: 1 Criterion B item (questions 1-5), 1 Criterion C item (questions 6-7), 2 Criterion D items (questions 8-14), and 2 Criterion E items (questions 15-20). A score of 2 (Moderately on the likert scale ) or higher is an endorsed symptom.
Notwithstanding the DSM related diagnostic criteria, scores of 33 or above are considered to be of clinical significance, and can serve as an alternative threshold for identifying significant PTSD symptoms that interfere with daily functioning (Bovin et al., 2016; Krüger-Gottschalk et al., 2017; Rosendahl et al., 2019).
A comparison graph is presented showing where the respondent’s score sits in comparison to the normative and PTSD samples, with shaded areas around the means indicating the two middle quartiles (between 25th and 75th percentile). This graph can help contextualise PCL-5 total scores in comparison to the distribution of responses among clinical and non-clinical groups. A cutoff score of 33 indicates the point at which symptoms are defined as clinically significant.
When administered more than once, longitudinal graphs are presented showing change in symptoms over time. A 12 point change during the course of treatment represents clinically significant change (Renyer, 2016).
A review of the PCL-5 using 51 studies demonstrated that the internal consistency for the total score ranged between .83 – .97 (Forkus et al., 2023). Test-retest reliability was tested across a range of time intervals and was found to range between .58 – .91 (Forkus et al., 2023). The PCL–5 total score showed moderate to strong correlations with other measures of PTSD (.44–.89; Forkus et al., 2023). Construct validity was assessed using group difference tests. Individuals with PTSD (vs. without PTSD) had a significantly higher PCL–5 total score (Fung et al., 2019) and individuals with probable PTSD (determined using recommended cutoff scores) had significantly greater mental functional impairment compared with those without probable PTSD (Forkus et al., 2023).
The normative percentiles are calculated from a combination of a non-clinical, non-trauma exposed group and a non-clinical but some trauma exposed group (N = 166, M = 16.47, SD = 16.29; Renyer, 2016). This group was combined to provide a more realistic non-clinical group where some of the group may have experienced some trauma (but not have PTSD) and some of the group have not experienced any trauma at all. Renyer (2016) also determined a reliable change score of 12. The clinical (PTSD) percentiles are calculated from a sample of military veterans in clinical care for PTSD (N = 468, M = 36.97, SD = 21.16; Bovin et al., 2016).
The distance from the normative mean described above was used to produce symptom descriptors:
Weathers, F.W., Litz, B.T., Keane, T.M., Palmieri, P.A., Marx, B.P., & Schnurr, P.P. (2013).The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at www.ptsd.va.gov.
Bovin MJ, Marx BP, Weathers FW, Gallagher MW, Rodriguez P, Schnurr PP, Keane TM. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. Psychol Assess. 2016 Nov;28(11):1379-1391. https://doi.org/10.1037/pas0000254
Forkus, S. R., Raudales, A. M., Rafiuddin, H. S., Weiss, N. H., Messman, B. A., & Contractor, A. A. (2023). The Posttraumatic Stress Disorder (PTSD) Checklist for DSM-5: A Systematic Review of Existing Psychometric Evidence. Clinical Psychology: A Publication of the Division of Clinical Psychology of the American Psychological Association, 30(1), 110–121. https://doi.org/10.1037/cps0000111
Fung, H. W., Chan, C., Lee, C. Y., & Ross, C. A. (2019). Using the Post-traumatic Stress Disorder (PTSD) Checklist for DSM-5 to Screen for PTSD in the Chinese Context: A Pilot Study in a Psychiatric Sample. Journal of Evidence-Based Social Work, 16(6), 643–651. https://doi.org/10.1080/26408066.2019.1676858
Krüger-Gottschalk, A., Knaevelsrud, C., Rau, H., Dyer, A., Schäfer, I., Schellong, J., & Ehring, T. (2017). The German version of the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): psychometric properties and diagnostic utility. BMC Psychiatry, 17(1), 379. https://doi.org/10.1186/s12888-017-1541-6
Renyer, D. (2016). Non-clinical normative data for ptsd checklist-5 (pcl-5) [PhD Thesis, Pacific University]. https://commons.pacificu.edu/work/sc/f8db5643-8fe5-4f09-ba9a-2b05a516d459
Rosendahl, J., Kisyova, H., Gawlytta, R., & Scherag, A. (2019). Comparative validation of three screening instruments for posttraumatic stress disorder after intensive care. Journal of Critical Care, 53, 149–154. https://doi.org/10.1016/j.jcrc.2019.06.016
As clinicians, we see it all the time. A client comes in complaining of insomnia, irritability, and difficulty concentrating. You might suspect depression, anxiety, or stress. But what if it’s trauma—and no one has ever asked?
PTSD is one of the most commonly under-identified conditions in adult mental health care. And when I say under-identified, I mean systematically missed—even when patients are sitting right in front of us showing every symptom.
In fact, a 2018 systematic review found that when mental health patients were screened for PTSD, about one in three met the diagnostic criteria. Yet only about one in ten of those cases were already documented in clinical records.
So why does this keep happening? The uncomfortable truth is that we’re not asking. Patients may not volunteer trauma experiences because they don’t connect their current symptoms with past trauma. In addition, avoidance itself is a symptom of PTSD, which may prevent people from talking about it. As a result, trauma often stays hidden.
Flashbacks can easily be mistaken for hallucinations. Avoidance may appear as depression. Hypervigilance can look like anxiety.
Trauma rarely walks into the clinic clearly labelled as PTSD. Instead, it shows up wearing other diagnoses. Patients can cycle through treatments that don’t work because clinicians are treating the wrong condition. Without routine trauma screening built into treatment protocols, these patterns often remain invisible.
I’m Dr. Hilah Kaufman, and today we’re taking a closer look at the PCL-5—a brief, validated tool that can help identify trauma that may have been there all along.
The PTSD Checklist for DSM-5, or PCL-5, is a 20-item self-report questionnaire designed to assess PTSD symptoms in adults who have experienced trauma.
Developed by the VA’s National Center for PTSD, it is well validated, widely used, and free. Different versions are available depending on clinical needs.
Each item corresponds directly to one of the 20 DSM-5 PTSD criteria, and each is rated on a 0 to 4 scale based on symptoms experienced over the past month. This produces a total score ranging from 0 to 80.
What makes the PCL-5 especially useful clinically is how the 20 items map onto the four DSM-5 symptom clusters for PTSD: re-experiencing, avoidance, negative alterations in cognition and mood, and hyperarousal. This structure helps clinicians see which symptoms are driving the distress.
Let’s look at an example.
Michael is a 24-year-old who came to therapy complaining of poor sleep, irritability, and difficulty concentrating. He didn’t mention trauma.
As part of routine screening, he completed the PCL-5 in NovoPsych. His total score was 32, just below the commonly used cutoff of 33. Looking at the NovoPsych report, that places him in the 83rd percentile compared to people without PTSD and around the 41st percentile compared to people with PTSD.
Then we examine the symptom clusters—and this is where the picture changes. NovoPsych averages each cluster on the same 0–4 scale and adds clear severity labels.
For Michael, avoidance was severe and re-experiencing was moderate. His negative cognitions and mood, as well as arousal symptoms, were both in the normal range.
This pattern doesn’t reflect generalized distress. It reflects a trauma-specific pattern driven by avoidance. And that distinction matters clinically. Even though Michael’s total score fell just below the cutoff, his responses met the DSM-5 symptom cluster criteria, supporting a provisional PTSD diagnosis.
Only later did Michael disclose the trauma itself: a serious car accident he experienced as a child that he had been actively avoiding thinking or talking about.
This illustrates the power of the PCL-5. It helps clinicians screen for PTSD, identify symptom patterns, support diagnosis, and monitor change over time.
When results suggest PTSD, that’s not the end of the process—it’s just the beginning. Clinicians should always confirm findings with further clinical assessment and then move toward trauma-focused, evidence-based care.
After six months of trauma-focused therapy, Michael’s total score dropped significantly. Research suggests that a 12-point change represents clinically meaningful improvement, allowing clinicians to track whether treatment is working.
NovoPsych also provides automatic longitudinal graphs, making it easy to see exactly which symptom clusters improved over time.
There are a few important things to keep in mind when using the PCL-5.
First, it is a screening tool that can support a provisional diagnosis, but it does not replace clinical judgement. Second, it is self-report, meaning responses depend on the client’s mood and willingness to disclose. Third, it reflects a 30-day snapshot, not the person’s entire clinical history.
Finally, it should not be administered blindly. Pair it with a trauma exposure screener, or ensure trauma exposure has already been established.
The PCL-5 is a powerful tool, but it should never be used in isolation.
Trauma rarely announces itself when patients walk through the door. Clinicians need structured ways to identify it.
The PCL-5 provides a systematic way to detect trauma that might otherwise remain hidden. It doesn’t replace clinical judgement—it sharpens it.
If you’re using NovoPsych, the PCL-5 can be administered digitally and scored automatically, with graphs, progress tracking, and a detailed interpretive report.
Somewhere in your caseload right now is undiagnosed trauma. The PCL-5 helps you find it.
